Erythropoietin Stimulating Agents Market to register USD 4.74 Bn growth – Technavio – QNT Press Release


NEW YORK, Sept. 14, 2022 /PRNewswire/ — Technavio has been monitoring the Erythropoietin Stimulating Agents Market, operating under the health care industry. The report estimates the market to register an incremental growth of USD 4.74 billionat a CAGR of 8.9% during the forecast period. The report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Request the Latest Free sample report.

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Competitors have to focus on differentiating their product offerings with unique value propositions to strengthen their foothold in the market.

Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. 3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., LG Chem Ltd., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. are among some of the major market participants.

The presence of a large pool of CKD patients has been instrumental in driving the growth of the market. However, stringent government regulations might hamper the market growth. Buy Sample Report.

Erythropoietin Stimulating Agents Market Segmentation

Based on geographic segmentation, 42% of the market’s originated from North America during the forecast period. In addition, the Epoetin Alfa category led the growth under the type segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the superfood powders market size.

  • Type
    • Epoetin Alfa
    • Epoetin Beta
    • Darbepoetin Alfa
    • Others
  • Geography
    • North America
    • Europe
    • Asia
    • Rest Of The World (ROW)

Erythropoietin Stimulating Agents Market Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The erythropoietin stimulating agents market report covers the following areas:

  • Erythropoietin Stimulating Agents Market Size
  • Erythropoietin Stimulating Agents Market Trends
  • Erythropoietin Stimulating Agents Market Industry Analysis

This study identifies the growing number of CKD dialysis centers in developing economies as one of the prime reasons driving the Erythropoietin Stimulating Agents Market growth during the next few years. Download Free Sample Report.

Erythropoietin Stimulating Agents Market Key Highlights

  • CAGR of the market during the forecast period
  • Detailed information on factors that will assist erythropoietin stimulating agents market growth during the next five years
  • Estimation of the erythropoietin stimulating agents market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the erythropoietin stimulating agents market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of the erythropoietin stimulating agents market, vendors

Related Reports

Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography – Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by $1.47bn from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 16.87%.

Pregabalin Market by Application and Geography – Forecast and Analysis 2022-2026: The pregabalin market share is expected to increase by USD 153.03 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 3.74%.

Erythropoietin Stimulating Agents Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 8.9%

Market growth 2022-2026

$4.74 billion

Market structure

Fragmented

YoY growth (%)

8.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center